ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Abstract Number: 2454

Longitudinal Analysis of B cell Remodeling in Systemic Lupus Erythematosus Following iPSC-Derived CAR T-cell Therapy
Abstract Number: 2455

Lupus Intervention Fatigue Trial: Preliminary Analysis of Baseline Data
Abstract Number: 2456

Predictors of Real-World Remission in Patients with SLE Initiating Belimumab in the USA
Abstract Number: 2457

Maternal, Embryo-Fetal And Neonatal Outcomes Following Belimumab Exposure During Pregnancy In Patients With Systemic Lupus Erythematosus
Abstract Number: 2458

Obecabtagene autoleucel (obe-cel), a CD19-targeting Autologous Chimeric Antigen Receptor T-cell Therapy (CAR T) with a fast off-rate binding domain, in Patients (pts) with Severe, Refractory Systemic Lupus Erythematosus (srSLE): Preliminary Results from the Phase I CARLYSLE Study
Abstract Number: 2459

Hydroxychloroquine Discontinuation in Systemic Lupus Erythematosus: A Retrospective Cohort Study with 3-Year Follow-Up
Abstract Number: 2460

Comparative Efficacy of Belimumab, Anifrolumab, and Rituximab in SLE: A Retrospective Analysis of Serological and Clinical Outcomes
Abstract Number: 2461

Targeting treatment-resistant Systemic Lupus Erythematosus through transcriptome-informed drug repurposing
Abstract Number: 2462

Precision Dosing is Needed to Establish Predictable Exposure to the Active Metabolite of Mycophenolate Mofetil (MMF) in Pediatric Lupus Nephritis (LN)
Abstract Number: 2463

Allogenic anti- CD19 CAR-T cells induce remission in refractory systemic lupus erythematosus
Abstract Number: 2464

IMC-002 (IMM0306), a First-in-Class Bi-specific Fusion Protein, Demonstrates Improvements in Systemic Lupus Erythematosus (SLE) Disease Activity Measures and Biomarkers in Patients with Moderate to Severe Active SLE in the Open-label Phase 1b/2 Study
Abstract Number: 2465

CD19/BCMA Dual-Targeting FasTCAR-T Cells GC012F (AZD0120) in patients with refractory Systemic Lupus Erythematosusm: an open-label, single-center Phase I study
Abstract Number: 2466

Efficacy and Safety Results of Zetomipzomib from the PALIZADE Phase 2b Clinical Trial in Patients with Lupus Nephritis
Abstract Number: 2467

Complete Renal Responses and Safety for Belimumab Versus Placebo in a Post Hoc Mycophenolate Mofetil Subgroup with Active Proliferative Lupus Nephritis
Abstract Number: 2468

RESET-SLE: Clinical Trial Evaluating Rese-cel (Resecabtagene Autoleucel), a Fully Human, Autologous 4-1BB CD19-CAR T Cell Therapy in Non-Renal SLE and Lupus Nephritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].